Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: The TB/HIV in Rio (THRio) study

Clinical Infectious Diseases

Volumn 60, Issue 4, 2015, Pages 639-645

  Golub, Jonathan E ^a   Cohn, Silvia ^a   Saraceni, Valeria ^b   Cavalcante, Solange C ^b,c   Pacheco, Antonio G ^d   Moulton, Lawrence H ^e   Durovni, Betina ^b,f   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Municipal Health Secretariat   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

durability; HIV; isoniazid; preventive therapy; tuberculosis

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ADULT; BRAZIL; COMPLICATION; FEMALE; FOLLOW UP; HIV INFECTIONS; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODEL; TUBERCULIN TEST; TUBERCULOSIS; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; BRAZIL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; ISONIAZID; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; TUBERCULIN TEST; TUBERCULOSIS; YOUNG ADULT;

EID: 84922346829     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu849     Document Type: Article

References (27)

1. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979; 119:827-30
2. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; CD000171
3. World Health Organization. Global tuberculosis report 2013. Geneva, Switzerland: WHO, 2013. WHO/HTM/2013.11
4. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342:268-72
5. de Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS 2001; 15:2129-35
6. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351:786-92
7. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801-8
8. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12:2447-57
9. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997; 337:315-20
10. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15:2137-47
11. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomized, double-blind, placebo-controlled trial. Lancet 2011; 377:1588-98
12. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365:11-20
13. Churchyard GJ, Fielding KL, Lewis JJ, et al; Thibela TB Study Team. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 2014; 370:301-10
14. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomized double-blind placebocontrolled trial. Lancet 2014; 384:682-90
15. Durovni B, Saraceni V, Moulton LH, et al. Lancet Infect Dis 2013; 13:852-8
16. Moulton LH, Golub JE, Durovni B, et al. Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clin Trials 2007; 4:190-9
17. Sistema de Informação sobre Mortalidade: Brasil. Ministério da Saúde.Sisitema de informaçes de mortalidade. Available at: http://www2.datasus.gov.br/DATASUS/index.php?area=040701. Accessed 27 November 2012
18. Sistema Nacional de Agravos de Notificação: Brasil. Ministério da Saúde.Sistema de informação de agravos de notificação. Available at: http://dtr2004.saude.gov.br/sinanweb. Accessed 27 November 2012
19. Ministério da Saúde. Recomendacoes para terapia anti-retroviral em adultos e adolescents infectados pelo HIV-2004. Brasilia: Ministerio da Saude, Secretaria de Vigilancia em Saude, Programa Nactional de DST e AIDS, 2004
20. Ministério da Saúde. Recomendacoes para terapia anti-retroviral em adultos e adolescents infectados pelo HIV-2007/2008. Brasilia: Documento preliminar. Ministerio da Saude, Secretaria de Vigilancia em Saude, Programa Nactional de DST e AIDS, 2008
21. Ministério da Saúde. Recomendacoes para terapia antiretroviral em adultos infectados pelo HIV-2008. Supplemento III: Tratamento e prevencao. Brasilia: Ministerio da Saude, Secretaria de Vigilancia em Saude, Depatamento de DST, AIDS e Hepatities Virais, 2010
22. Conde MB, Melo FA, Marques AM, et al. III Brazilian Thoracic Association guidelines on tuberculosis. J Bras Pneumol 2009; 35:1018-48
23. Saraceni V, Cohn S, Cavalcante SC, et al. Prevalent tuberculosis (TB) at HIV diagnosis in Rio de Janeiro, Brazil: the TB/HIV in Rio (THRio) Cohort. J Acquir Immune Defic Syndr 2014; 67:98-101
24. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11:875-82
25. Houben RM, Sumner T, Grant AD, White RG. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci U S A 2014; 111:5325-30
26. Corbett EL, Churchyard GJ, Clayton TC, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000; 14: 2759-68
27. Ministério da Saúde. Secretaria de Vigilância em Saúde. O controle da tuberculosis no Brasil: avancos, inovacoes e desafios. Boletim Epidemiologico 2014; 44:1-13